	DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT OFFICE	ADDRESS AND PHONE NUMBER		DATE(S) OF INSPECTION		
FLA-DO	Place, Suite 200		8/22-26, 29, 31/2016		
			8/22-20, 29, 51/20:0		
Maitland, FL (407) 475-470			FEI NUMBER		
,	nation: www.fda.gov/oc/industry		3005630265		
	OF INDIVIDUAL TO WHOM REPORT IS ISSUED				
To: Christopher M. Schulte, Owner					
	per M. Schulte, Owner	STREET ADDRESS			
FIRM NAME					
	thecary, Inc. DBA Everwell Specialty Pharmacy	6506 N. Davis Highwa			
CITY, STATE AND		TYPE OF ESTABLISHMENT I			
Pensacola, FL	32504	Producer of Sterile and	Non-sterile Drug Produc	ts	
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE. DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:					
Sterile Drug Production					
J					
OBSERVA	TION I				
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.					
Specifically, the gowns worn during aseptic production are stored on a shelf next to the sink in the anteroom where they can be splashed with water during handwashing.					
OBSERVATION 2					
Equipment, materials, and/or supplies are not disinfected prior to entering the aseptic processing areas.					
Specifically. General Aseptic Technique SOP 5.2.1 states that work surfaces of the aseptic production area shall be cleaned prior to use. While observing the production of Methylcobalamin Lot 08242016@18 it was noted that the inside surface of the ISO5 unit was not sanitized prior to production.					
	in the state of th		Add	Continuation Fage	
			1	NO AND PERSONAL PROPERTY.	
			,		
-	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TIT	LE (Print or Type)	DATE ISSUED	
SEE REVERSE OF THIS PAGE	Jaluar -	Joshua P. Wireman, Invest	igator	08/31/2016	
				CHE ZONIO CONSTRUIS CONTROL PRESIDEN	
FORM FDA 483	3 (9/08) PREVIOUS EDITION OBSOLETE	SPECTIONAL OBSERV	ATIONS	Page 1 of 3	

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DATE(S) OF INSPECTION DISTRICT OFFICE ADDRESS AND PHONE NUMBER 8/22-26, 29, 31/2016 FLA-DO 555 Winderly Place, Suite 200 FEI NUMBER Maitland, FL 32751 (407) 475-4700 3005630265 Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: Christopher M. Schulte, Owner STREET ADDRESS FIRM NAME 6506 N. Davis Highway Pensacola Apothecary, Inc. DBA Everwell Specialty Pharmacy TYPE OF ESTABLISHMENT INSPECTED CITY, STATE AND ZIP CODE Producer of Sterile and Non-sterile Drug Products Pensacola, FL 32504 Non-Sterile Drug Production OBSERVATION 3 Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release. Specifically finished non-sterile products are not tested for potency and unacceptable microorganisms. For example Benzocaine/Lidocaine/Tetracaine 20%-8%-4% Lipoderm Cream Lot #06102016@12 was not tested for potency and unacceptable microorganisms. OBSERVATION 4 There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Specifically mixing instructions do not include duration of mixing to assure the replication of the process. For example, the logged formula worksheet instructions for T4-T3 (Dye-Free Veggie Cap) 85 MCG - 15 MCG Capsule Lot 08182016@10 state to mix all powders with agitation in the Turbula however the mixing time is not included in the instructions Add Continuation Page EMPLOYEE(\$) SIGNATURE EMPLOYEE(S) NAME AND TITLE (Print or Type) DATE ISSUED OF THIS Joshua P. Wireman, Investigator 08/31/2016

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DATE(S) OF INSPECTION DISTRICT OFFICE ADDRESS AND PHONE NUMBER FLA-DO 8/22-26, 29, 31/2016 555 Winderly Place, Suite 200 FEI NUMBER Maitland, FL 32751 (407) 475-4700 3005630265 Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: Christopher M. Schulte, Owner FIRM NAME STREET ADDRESS Pensacola Apothecary, Inc. DBA Everwell Specialty Pharmacy 6506 N. Davis Highway TYPE OF ESTABLISHMENT INSPECTED CITY, STATE AND ZIP CODE Pensacola, FL 32504 Producer of Sterile and Non-sterile Drug Products **OBSERVATION 5** Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. Specifically the Cleaning And Maintenance of the Non-Sterile Compounding Area SOP 4.15.1 has not been validated to assure removal of residual product and sanitizing agents and prevent crossover between batches. Add Continuation Page EMPLOYEE(S) SIGNATURE EMPLOYEE(S) NAME AND TITLE (Print or Type) DATE ISSUED Joshua P. Wireman, Investigator 08/31/2016